Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer

Clinical Cancer Research

Volumn 7, Issue 12, 2001, Pages 4060-4066

  Fedarko, Neal S ^a   Jain, Alka ^a   Karadag, Abdullah ^b   van Eman, Matthew R ^b   Fisher, Larry W ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; GLYCOPROTEIN; INTEGRIN; OSTEOPONTIN; SIALOPROTEIN; TRIPEPTIDE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC;

BREAST NEOPLASMS; COLONIC NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; OSTEOPONTIN; REFERENCE VALUES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SIALOGLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035671826     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. The solution structures of two SIBLING proteins, bone sialoprotein and osteopontin, by NMR
2. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer
3. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival
4. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers
5. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer
6. Expression of bone matrix proteins in human breast cancer: Potential roles in microcalcification formation and in the genesis of bone metastases
7. Ectopic expression of bone sialoprotein in human thyroid cancer
8. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease
9. Neoplastic odontogenic epithelial cells express bone sialoprotein
10. The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype
11. Osteopontin expression in a group of lymph node negative breast cancer patients
12. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment
13. Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer
14. Osteopontin expression and distribution in human carcinomas
15. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development
16. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers
17. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis
18. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma
19. Osteopontin expression in lung cancer
20. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas
21. Co-expression of osteopontin and CD44v9 in gastric cancer
22. Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP)
23. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo
24. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts
25. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells
26. Calcium signals in prostate cancer cells: Specific activation by bone- matrix proteins
27. Osteopontin: Possible role in prostate cancer progression
28. Factor H binding to bone sialoprotein and osteopontin enables molecular cloaking of tumor cells from complement-mediated attack
29. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival
30. Quantification of osteopontin in human plasma with an ELISA: Basal levels in pre- and postmenopausal women
31. Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone
32. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases